The research of this project is focused on a newly discovered mechanism that operates as an important determinant of the growth of tumors. Carcinomas in general, and breast cancers in particular, are known to depend on recruited mesenchymal cells that form the tumor-associated stroma and provide vital physiologic support to the epithelial cancer cells. These mesenchymal cells derive from normal host tissue adjacent to the growing tumor as well as from progenitor cells that originate in the bone marrow. However, the mechanisms that allow the recruitment of such bone marrow progenitors and the importance of their role in overall tumor growth remain poorly understood. The research described here indicates that the slow growth of indolent tumors can be attributed in some cases, and perhaps in many, to the inability of the cancer cells to effectively recruit stromal progenitors from the marrow. This defect, in turn, can be ascribed to the fact that these indolent tumor cells are unable to release endocrine signals that perturb the bone marrow, causing it to activate and mobilize into the circulation stromal precursor cells that may subsequently be recruited by the tumor cells. Without this bone marrow-activating power, these indolent tumor cells fail to effectively recruit stromal precursors from the circulation and remain either dormant or slowly growing. In contrast, some vigorously growing tumors are endowed with the endocrine signaling ability, which we term

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA080111-15
Application #
8449503
Study Section
Special Emphasis Panel (ZCA1-GRB-S)
Project Start
Project End
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
15
Fiscal Year
2013
Total Cost
$275,105
Indirect Cost
$37,141
Name
Whitehead Institute for Biomedical Research
Department
Type
DUNS #
120989983
City
Cambridge
State
MA
Country
United States
Zip Code
02142
Bailey, Shannon T; Westerling, Thomas; Brown, Myles (2015) Loss of estrogen-regulated microRNA expression increases HER2 signaling and is prognostic of poor outcome in luminal breast cancer. Cancer Res 75:436-45
Hines, William C; Su, Ying; Kuhn, Irene et al. (2014) Sorting out the FACS: a devil in the details. Cell Rep 6:779-81
Yamamoto, Shoji; Wu, Zhenhua; Russnes, Hege G et al. (2014) JARID1B is a luminal lineage-driving oncogene in breast cancer. Cancer Cell 25:762-77
Jeselsohn, Rinath; Yelensky, Roman; Buchwalter, Gilles et al. (2014) Emergence of constitutively active estrogen receptor-? mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res 20:1757-67
Lu, Haihui; Clauser, Karl R; Tam, Wai Leong et al. (2014) A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. Nat Cell Biol 16:1105-17
Pathania, Shailja; Bade, Sangeeta; Le Guillou, Morwenna et al. (2014) BRCA1 haploinsufficiency for replication stress suppression in primary cells. Nat Commun 5:5496
Hu, Yiduo; Petit, Sarah A; Ficarro, Scott B et al. (2014) PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair. Cancer Discov 4:1430-47
McAllister, Sandra S; Weinberg, Robert A (2014) The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat Cell Biol 16:717-27
Hill, Sarah J; Rolland, Thomas; Adelmant, Guillaume et al. (2014) Systematic screening reveals a role for BRCA1 in the response to transcription-associated DNA damage. Genes Dev 28:1957-75
Hill, Sarah J; Clark, Allison P; Silver, Daniel P et al. (2014) BRCA1 pathway function in basal-like breast cancer cells. Mol Cell Biol 34:3828-42

Showing the most recent 10 out of 89 publications